Prof. Hao Peng | RNA Epigenetic | Best Researcher Award

Prof. Hao Peng | RNA Epigenetic | Best Researcher Award

Guangdong Provincial People’s Hospital | China

AUTHOR PROFILE

Scopus

👩‍⚕️PROFESSOR YINGFEN YING: A DISTINGUISHED MEDICAL PROFESSIONAL🌍

📘 EARLY ACADEMIC PURSUITS

Prof. Hao Peng’s academic journey began with graduate studies at Sun Yat-sen University Cancer Center, where he laid the groundwork for his expertise in oncology. Following this, he undertook postdoctoral research at the First Affiliated Hospital of Sun Yat-sen University. This period marked his immersion in groundbreaking research, fostering a deep interest in RNA epigenetic modifications and their role in cancer biology.

💼 PROFESSIONAL ENDEAVORS

Currently a Professor and Surgical Oncologist at Guangdong Provincial People’s Hospital in China, Prof. Peng combines clinical practice with impactful research. His dual roles allow him to contribute both to patient care and the academic community, exemplifying the integration of clinical insights into scientific discovery.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON RNA EPIGENETIC

Prof. Peng’s primary research interests revolve around RNA epigenetic modifications in cancer, particularly:

  • tRNA m7G modification
  • 18S rRNA m6A modification
  • 28S rRNA m6A modification

He has elucidated how these modifications regulate mRNA translation and promote cancer progression. His findings have significantly enhanced the understanding of molecular mechanisms underlying oncogenesis.

🌍 IMPACT AND INFLUENCE

Prof. Peng has established himself as a thought leader in oncology, publishing several high-impact papers as the first and corresponding author in prestigious journals, including:

  • Nature Metabolism
  • Cell Reports
  • Cell Chemical Biology
  • Oncogene

These publications have contributed to advancing RNA epigenetics and its implications in cancer biology.

📊 ACADEMIC CITATIONS

With a growing citation impact, Prof. Peng’s research is widely referenced in the field, highlighting his influence on oncology research. His innovative work in RNA modifications has positioned him as a respected voice in his domain, shaping future studies in cancer therapeutics.

🔑 LEGACY AND FUTURE CONTRIBUTIONS

Prof. Peng has hosted multiple national research funds, emphasizing his role in advancing cancer research in China. His dedication to mentorship and collaboration ensures a lasting legacy in oncology. His ongoing research in RNA modifications holds promise for the development of novel therapeutic strategies, bridging the gap between molecular discoveries and clinical applications.

🏆 RECOGNITIONS AND LEADERSHIP

As a leader in the field, Prof. Peng continues to drive innovation in oncology. His contributions have earned him national recognition, solidifying his reputation as a pioneer in RNA epigenetics and its translational potential in cancer treatment.

🌟CONCLUSION 

Prof. Hao Peng’s exemplary career demonstrates the transformative impact of integrating molecular research with clinical practice. His pioneering work in RNA epigenetic modifications has reshaped the understanding of cancer progression and mRNA translation regulation. With a robust portfolio of influential publications, funded research projects, and a commitment to advancing oncology, Prof. Peng is not only contributing to the present scientific landscape but also paving the way for future breakthroughs in cancer therapeutics. His dedication to innovation, mentorship, and collaboration ensures a lasting legacy in the fight against cancer, inspiring both his peers and the next generation of researchers.

 

📊🔬NOTABLE PUBLICATION:
  • N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis
    • Authors: Han, H.; Yang, C.; Ma, J.; …; Choe, J.; Lin, S.
    • Journal: Nature Communications
    • Year: 2022

 

  • N6-methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation
    • Authors: Peng, H.; Chen, B.; Wei, W.; …; Kuang, M.; Lin, S.
    • Journal: Nature Metabolism
    • Year: 2022

 

  • N7-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma
    • Authors: Chen, B.; Jiang, W.; Huang, Y.; …; Wu, L.; Peng, H.
    • Journal: Oncogene
    • Year: 2022

 

  • N6-methyladenosine modification in 18S rRNA promotes tumorigenesis and chemoresistance via HSF4b/HSP90B1/mutant p53 axis
    • Authors: Chen, B.; Huang, Y.; He, S.; …; Wu, L.; Peng, H.
    • Journal: Cell Chemical Biology
    • Year: 2023

 

  • Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma
    • Authors: Peng, H.; Chen, L.; Mao, Y.-P.; Tian, L.; Liu, L.-Z.
    • Journal: Oral Oncology
    • Year: 2021